공유는 배려입니다!


As part of a new strategic collaboration with KAEDI Biotech Inc., Porton Biologics Ltd. will provide KAEDI with CMC services for CAR-T projects with its end-to-end CDMO platform, to help accelerate development. 

The results of the companies’ first project in collaboration, KD-025 CAR-T, have been published and there is an ongoing multi-centre clinical trial of KD-025 CAR-T POC, with cases of clinical infusions demonstrating no obvious toxicities and side effects. An IND is being applied for as well. 

“KAEDI has successfully developed a pipeline of several CAR-T new drug candidates for malignant solid tumours. We believe that Portonbio’s excellent technical team and professional CDMO platform can help KAEDI quickly and efficiently promote the drug candidates in our pipeline and accelerate the development process of our cell therapy drugs,” said Dr. Hongjiu Dai, Chairman and CEO of KAEDI.

Mr. Nianfeng Ju, Chairman and CEO of Portonbio, added that “Portonbio has established an integrated CDMO service platform for plasmids, viral vectors and cell therapy products, and has an experienced expert team and unique technical advantages. We hope to accelerate the marketing process of KAEDI CAR-T products through this cooperation, jointly promote the breakthrough of cell therapy products in the field of solid tumour, and enable the patients’ early-access to the therapies.”

About KAEDI

KAEDI is a clinical stage biotech company that has successfully developed several R&D pipelines of CAR-T first-in-class drugs for malignant solid tumours, leveraging on its advanced synthetic biology technology platform, KD SmCARTM

The pre-clinical research results of KD-025 CAR-T targeting liver cancer and glioma were published in the Journal for ImmunoTherapy of Cancer, Cancer Immunology Research and the American Society of Clinical Oncology (ASCO). For more information, visit http://www.cartbiomed.com/china/.

About PortonbioA subsidiary of Porton Pharma Solutions Ltd., Portonbio provides an integrated cGMP-compliant manufacturing platform ranging from plasmids, viral vectors and cell therapeutics to biotech companies, allowing for clinical to commercial production. Portonbio provides innovative, flexible development and manufacturing solutions to the complex challenges in the GCT space. For more information, visit https://www.portonbio.com/.

(Source: Cision, 2nd June 2021)